$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415048801 Filed on August 13, 2015

Income Statement

Concept	2015 Q2	2014 Q2	2014 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$420.0K	$350.0K
YoY Change	135.71%	-43.24%	-37.5%
% of Gross Profit
Research & Development	$1.375M	$877.0K	$680.0K
YoY Change	56.78%	18.19%	30.27%
% of Gross Profit
Depreciation & Amortization	$30.00K	$20.00K	$30.00K
YoY Change	50.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$1.375M	$1.294M	$1.031M
YoY Change	6.26%	-12.86%	-4.63%
Operating Profit	-$2.363M	-$1.294M	-$2.111M
YoY Change	82.61%	-13.73%	95.1%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$100.0K	-$690.0K	-$1.080M
YoY Change	-114.49%	3350.0%
Pretax Income	-$2.270M	-$1.980M	-$2.110M
YoY Change	14.65%	32.0%	95.37%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.265M	-$1.984M	-$2.111M
YoY Change	14.16%	30.7%	95.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$123.0K	-$159.4K	-$179.6K
COMMON SHARES
Basic Shares Outstanding	18.48M shares		176.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2014 Q2	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.70M	$11.33M	$3.030M
YoY Change	73.87%	346.06%	-16.76%
Cash & Equivalents	$1.301M	$11.33M	$3.027M
Short-Term Investments	$18.39M
Other Short-Term Assets	$110.0K	$50.00K	$30.00K
YoY Change	120.0%	-64.29%	-25.0%
Inventory
Prepaid Expenses		$48.00K	$34.00K
Receivables	$250.0K	$830.0K	$790.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.06M	$12.21M	$3.853M
YoY Change	64.33%	271.03%	-10.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$282.0K	$302.0K	$327.0K
YoY Change	-6.62%	14.83%	42.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$20.00K	$10.00K
YoY Change	0.0%	-91.67%	-95.45%
Total Long-Term Assets	$303.0K	$317.0K	$340.0K
YoY Change	-4.42%	-37.1%	-24.44%
TOTAL ASSETS
Total Short-Term Assets	$20.06M	$12.21M	$3.853M
Total Long-Term Assets	$303.0K	$317.0K	$340.0K
Total Assets	$20.36M	$12.52M	$4.193M
YoY Change	62.59%	230.1%	-11.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$755.0K	$757.0K	$326.0K
YoY Change	-0.26%	102.95%	30.4%
Accrued Expenses	$1.505M	$755.0K	$1.034M
YoY Change	99.34%	24.59%	56.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.526M	$1.782M	$1.607M
YoY Change	41.75%	48.5%	51.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$140.0K	$1.730M
YoY Change	-100.0%	-41.67%	723.81%
Total Long-Term Liabilities	$0.00	$142.0K	$1.726M
YoY Change	-100.0%	-40.83%	721.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.526M	$1.782M	$1.607M
Total Long-Term Liabilities	$0.00	$142.0K	$1.726M
Total Liabilities	$2.526M	$1.924M	$3.333M
YoY Change	31.29%	33.7%	162.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.15M
YoY Change
Common Stock		$67.10M	$55.38M
YoY Change		27.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.84M	$10.60M	$860.0K
YoY Change
Total Liabilities & Shareholders Equity	$20.36M	$12.52M	$4.193M
YoY Change	62.57%	230.45%	-11.73%

Cashflow Statement

Concept	2015 Q2	2014 Q2	2014 Q1
OPERATING ACTIVITIES
Net Income	-$2.265M	-$1.984M	-$2.111M
YoY Change	14.16%	30.7%	95.1%
Depreciation, Depletion And Amortization	$30.00K	$20.00K	$30.00K
YoY Change	50.0%	0.0%	0.0%
Cash From Operating Activities	-$1.650M	-$970.0K	-$391.0K
YoY Change	70.1%	-8.75%	-41.64%
INVESTING ACTIVITIES
Capital Expenditures	-$16.00K	$0.00	$94.00K
YoY Change		-100.0%	370.0%
Acquisitions
YoY Change
Other Investing Activities	-$530.0K	$0.00	$10.00K
YoY Change		-100.0%	-98.99%
Cash From Investing Activities	-$550.0K	-$2.000K	-$85.00K
YoY Change	27400.0%	-96.49%	-108.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$9.658M	$0.00
YoY Change	-100.0%		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	$9.273M	$0.00
YoY Change	-99.89%	132371.43%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.650M	-$970.0K	-$391.0K
Cash From Investing Activities	-550.0K	-$2.000K	-$85.00K
Cash From Financing Activities	10.00K	$9.273M	$0.00
Net Change In Cash	-2.190M	$8.301M	-$476.0K
YoY Change	-126.38%	-845.82%	-186.39%
FREE CASH FLOW
Cash From Operating Activities	-$1.650M	-$970.0K	-$391.0K
Capital Expenditures	-$16.00K	$0.00	$94.00K
Free Cash Flow	-$1.634M	-$970.0K	-$485.0K
YoY Change	68.45%	-12.53%	-29.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
CY2014Q2	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
CY2015Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	20000	USD
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	20000	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	20000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	20000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	282000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313000	USD
CY2015Q2	us-gaap	Assets Assets	20363000	USD
CY2014Q4	us-gaap	Assets Assets	9911000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	755000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1542000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1505000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1347000	USD
CY2015Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	266000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	224000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2526000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3113000	USD
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	123000	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	123000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	2526000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	3236000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66154000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61653000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	877000	USD
CY2015Q2	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-98000	USD
CY2014Q2	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	690000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2265000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1984000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.12
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.16
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18450464	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12416892	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	674000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2497000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2014	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	198000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1024000	USD
CY2014	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9554000	USD
CY2014	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	108000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	668000	USD
	bcli	Exercise Of Liability Classified Warrants ExerciseOfLiabilityClassifiedWarrants	145000	USD
	bcli	Exercise Of Equity Classified Warrants ExerciseOfEquityClassifiedWarrants	2333000	USD
	bcli	Exercise And Reissuance Of Warrants Value ExerciseAndReissuanceOfWarrantsValue	12409000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	47000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	50000	USD
CY2014	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
CY2014Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	176000	USD
CY2015Q2	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-362000	USD
CY2014Q2	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	53000	USD
CY2015Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	321000	USD
CY2014	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	701000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-9246000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1762000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	200000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-79000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-787000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	529000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3587000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1361000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-671000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-64000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	668000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	298000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	108000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	110000	USD
CY2015Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	24000	USD
CY2014Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	25000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	691000	USD
CY2015Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-33000	USD
CY2014Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-256000	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-167000	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	431000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1650000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-970000	USD
CY2015Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	108000	USD
CY2014Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	14104000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-7000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-14120000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-87000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14757000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9273000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2950000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7825000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11328000	USD
CY2015Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	USD
CY2014Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2014Q2	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
CY2015Q2	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-539000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	130000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	42000	USD
CY2015Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	42000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-555000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9273000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2193000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8301000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3494000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3027000	USD
	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
	us-gaap	Share Based Compensation ShareBasedCompensation	668000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	408000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	321000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	176000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18480957	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15281497	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15281497	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18480957	shares
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1633000	USD
CY2015Q2	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014Q2	us-gaap	Stock Issued1 StockIssued1	1633000	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	130000	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
CY2015Q2	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
CY2014Q2	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9658000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12409000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2015Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2015Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9658000	USD
CY2014Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	20000	USD
CY2009Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	74667	shares
CY2014Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
	bcli	Interest Bearing Bank Deposits Maturity Date InterestBearingBankDepositsMaturityDate	P4M
CY2014	bcli	Interest Bearing Bank Deposits Maturity Date InterestBearingBankDepositsMaturityDate	P5M
	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	2348000	USD
	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	215000	USD
CY2015Q2	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	0	USD
CY2014Q2	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	215000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4568000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2325000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2363000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1294000	USD

Files In Submission

Name	View Source	Status
0001144204-15-048801-index-headers.html	Edgar Link	pending
0001144204-15-048801-index.html	Edgar Link	pending
0001144204-15-048801.txt	Edgar Link	pending
0001144204-15-048801-xbrl.zip	Edgar Link	pending
bcli-20150630.xml	Edgar Link	completed
bcli-20150630.xsd	Edgar Link	pending
bcli-20150630_cal.xml	Edgar Link	unprocessable
bcli-20150630_def.xml	Edgar Link	unprocessable
bcli-20150630_lab.xml	Edgar Link	unprocessable
bcli-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v416801_10q.htm	Edgar Link	pending
v416801_ex31-1.htm	Edgar Link	pending
v416801_ex31-2.htm	Edgar Link	pending
v416801_ex32-1.htm	Edgar Link	pending
v416801_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q2 Form 10-Q Financial Statement

#000114420415048801 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q2 Form 10-Q Financial Statement

#000114420415048801 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli